Julian Charles Baker
Independent Chairman of the BoardMr. Julian Charles Baker, also known as Jim, is Chief Corporate Affairs Officer of Damora Therapeutics, Inc. Mr. Baker is Independent Chairperson of Denali Therapeutics Inc. from June 3, 2025. Mr. Baker has been a Director of Incyte Corp. since November 26, 2001 and serves as its Chairman of the Board since June 26, 2025. He had been Lead Director of Incyte Corporation until June 26, 2025 and served as its Vice Chairman since 2014. Mr. Baker joined the Incyte Corporation on November 26, 2001. Mr. Baker serves as Independent Chairman of the Board at Madrigal Pharmaceuticals, Inc. since June 15, 2023. He serves as a Co-Managing Member and Limited Partner at Baker Bros. Advisors LP. Mr. Baker served as a Director at Alumis Inc. until June 07, 2024. He serves as Senior Vice President, Corporate Affairs at Blueprint Medicines Corporation and was its Vice President of Corporate Affairs. Mr. Baker served as Independent Director of Prelude Therapeutics Inc. since January 25, 2021 until June 13, 2025. Mr. Baker career as a portfolio Manager began in 1994 till 1999 when he co-founded a biotechnology investing Partnership with the Tisch Financial Management from 1994 to 1999. Mr. Baker is a Managing Member of Baker Brothers Investments. Mr. Baker is a Managing Partner of Baker-Tisch Investments. He previously served an Executive Director of Market Development at Idera Pharmaceuticals, Inc. since January 2015 until 2018. From 1988 to 1993, Mr. Baker was working at the private equity investment arm of Credit Suisse First Boston Corporation. He has been an Independent Director of ACADIA Pharmaceuticals Inc. since December 11, 2015. Mr. Baker had served as an Executive Director of Idera Pharmaceuticals, Inc. from March 10, 2014 to September 18, 2018. He served as an Independent Director and Lead Independent Director of Genomic Health, Inc. from January 2001 to November 8, 2019. Mr. Baker serves as the Director of Tapestry Pharmaceuticals, Inc. He served as a Member of Advisory Board of Elm Street Ventures. Mr. Baker served as a Director of Cellegy Pharmaceuticals. Mr. Baker served as a Director of Theravance Inc. from January 1999 to April 25, 2007. He served as a Director of Trimeris Inc. since April 2004. Mr. Baker served as an Independent Director of Neurogen Corporation. He served as Director of ProtoGene laboratories, Inc. Mr. Baker holds a Bachelor of Arts in Social Studies, Magna Cum Laude, from Harvard University.
Positions
- Company NameMadrigal Pharmaceuticals, Inc.Stock CodeMDGLPositionIndependent Chairman of the BoardColleagues
- WJWilliam J. SiboldCEO, President & Director
- JCJulian Charles BakerIndependent Chairman of the Board
- RARebecca A. TaubFounder, Senior Scientific & Medical Advisor and Director
- MCMardi C. DierExecutive VP & CFO
- SKShannon KelleyExecutive VP, Chief Legal Officer & Corporate Secretary
- CHCarole HuntsmanExecutive VP & Chief Commercial Officer
- RSRichard Steven LevyIndependent Director
- DJDaniel J. BrennanIndependent Director
- Company NameIncyte CorporationStock CodeINCYPositionIndependent Chairman of the BoardColleagues
- WJWilliam J. MeuryCEO & Director
- PJPablo J. CagnoniPresident and Global Head of R&D
- TTThomas TrayPrincipal Financial Officer, VP of Finance & Chief Accounting Officer
- SHSteven H. SteinExecutive VP, Head of Late-stage Development & Chief Medical Officer
- MKMohamed Khairie IssaExecutive Vice President & Head of U.S. Commercial
- JBJean-Jacques BienaimeIndependent Director
- PJPaul J. ClancyIndependent Director
- JAJacqualyn A. FouseIndependent Director
- Company NameDenali Therapeutics Inc.Stock CodeDNLIPositionIndependent ChairpersonColleagues
- RJRyan J. WattsCo-Founder, President, CEO & Director
- JCJulian Charles BakerIndependent Chairperson
- AOAlexander O. SchuthCo-Founder, CFO, COO & Secretary
- DADana AndersenChief Technical and Manufacturing Officer
- JLJoe LewcockChief Scientific Officer
- CWChris WalshGeneral Counsel
- JTJay T. FlatleyIndependent Director
- PSPeter S. KleinIndependent Director
- JEJennifer E. CookIndependent Director
